Physician profile
Lucinda Kohn
NPI 1346669561
$5,175.25
in general payments reported to CMS, 2019-2025
14 companies · $5,067 in 2025
The $5,067 reported for 2025 was more than what 83% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $108 · 2025: $5,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,400 · Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,400.00 |
| Food and Beverage | $775.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $4,400.00 | 2025 | Olumiant |
| Arcutis Biotherapeutics, INC. | $188.52 | 2024-2025 | Zoryve |
| Ucb, INC. | $104.42 | 2025 | Bimzelx |
| Pfizer INC. | $77.18 | 2025 | |
| Incyte Corporation | $75.04 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $66.33 | 2025 | |
| Lilly USA, LLC | $57.41 | 2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $48.23 | 2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.83 | 2025 | Jublia |
| Genzyme Corporation | $36.76 | 2025 | |
| Abbvie INC. | $25.22 | 2025 | |
| Verrica Pharmaceuticals INC. | $19.88 | 2025 | Ycanth |
| Organon LLC | $16.36 | 2025 | Vtama |
| Botanix Sb INC | $16.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucinda Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.